全文获取类型
收费全文 | 1259篇 |
免费 | 99篇 |
国内免费 | 21篇 |
专业分类
耳鼻咽喉 | 9篇 |
儿科学 | 58篇 |
妇产科学 | 16篇 |
基础医学 | 139篇 |
口腔科学 | 17篇 |
临床医学 | 113篇 |
内科学 | 382篇 |
皮肤病学 | 24篇 |
神经病学 | 100篇 |
特种医学 | 144篇 |
外科学 | 121篇 |
综合类 | 33篇 |
预防医学 | 102篇 |
眼科学 | 5篇 |
药学 | 70篇 |
肿瘤学 | 46篇 |
出版年
2021年 | 21篇 |
2020年 | 16篇 |
2019年 | 13篇 |
2018年 | 7篇 |
2017年 | 13篇 |
2016年 | 12篇 |
2015年 | 20篇 |
2014年 | 24篇 |
2013年 | 35篇 |
2012年 | 23篇 |
2011年 | 30篇 |
2010年 | 39篇 |
2009年 | 48篇 |
2008年 | 23篇 |
2007年 | 38篇 |
2006年 | 35篇 |
2005年 | 41篇 |
2004年 | 31篇 |
2003年 | 34篇 |
2002年 | 29篇 |
2001年 | 59篇 |
2000年 | 32篇 |
1999年 | 36篇 |
1998年 | 43篇 |
1997年 | 49篇 |
1996年 | 41篇 |
1995年 | 45篇 |
1994年 | 20篇 |
1993年 | 28篇 |
1992年 | 28篇 |
1991年 | 29篇 |
1990年 | 29篇 |
1989年 | 34篇 |
1988年 | 35篇 |
1987年 | 46篇 |
1986年 | 34篇 |
1985年 | 26篇 |
1984年 | 28篇 |
1983年 | 18篇 |
1982年 | 23篇 |
1981年 | 8篇 |
1980年 | 17篇 |
1978年 | 10篇 |
1977年 | 13篇 |
1976年 | 11篇 |
1975年 | 14篇 |
1974年 | 14篇 |
1972年 | 12篇 |
1971年 | 11篇 |
1967年 | 7篇 |
排序方式: 共有1379条查询结果,搜索用时 15 毫秒
1.
Uptake of iodine-123 MIBG by pheochromocytomas, paragangliomas, and neuroblastomas: a histopathological comparison 总被引:2,自引:0,他引:2
J Bomanji D A Levison W D Flatman T Horne P M Bouloux G Ross K E Britton G M Besser 《Journal of nuclear medicine》1987,28(6):973-978
The percentage uptake of [123I]metaiodobenzylguanidine (MIBG) by tumors of the paraganglion system is compared with the number of neurosecretory granules (assessed by both light and electron microscopy) in the subsequently resected tumors in six patients. Iodine-123 MIBG was injected intravenously; the tumor uptake of [123I]MIBG varied between 0.001% and 0.14% of the injected dose per gram of tumor tissue at 22 hr. The number of neurosecretory granules in tissue sections was scored on a scale of I-III. A direct proportional correlation was found between the percentage uptake of [123I]MIBG by the tumor and the number of neurosecretory granules in the tissue sections but not with plasma or urinary catecholamines. This technique for imaging reflects the storage status of the tumor better than plasma and urinary catecholamine measurements. 相似文献
2.
S. Tsagarakis Feng Ge L. H. Rees G. M. Besser A. Grossman 《Journal of neuroendocrinology》1989,1(2):129-133
While extensive evidence suggests that adrenoceptors play an important role in the control of growth hormone in the rat, there are few studies involving the direct measurement of growth hormone-releasing hormone (GHRH). We have therefore developed a radioimmunoassay for rat GHRH, and used it to investigate the modulation of GHRH release by noradrenaline from incubated rat hypothalamus in vitro. The GHRH radioimmunoassay had no significant cross-reactivity with other hypothalamic or GHRH-related peptides, and was sensitive to 4 pg/tube; intra- and interassay coefficients of variation were 6% and 12% respectively. Single incubated rat hypothalami produced a stable and readily measurable output of GHRH in successive 20 min incubations after an initial 60 min preincubation; the release of GHRH was increased in the presence of 56 mM KCI, but did not respond to KCI-depolarization when calcium was excluded from the medium. Stimulated GHRH release was identical to synthetic rat GHRH(1–43) on high-performance liquid chromatography and Sephadex G-75 chromatography.
Noradrenaline stimulated GHRH secretion in a dose-dependent manner in the concentration range 10−10 — 10−6 M, with a plateau in response at 10−7 M. Stimulation with noradrenaline 10−7 M was blocked by idazoxan 10−5 M and attenuated by thymoxamine 10−5 M, but was unaffected by timolol 10−5 M. Both the α2 -adrenoceptor agonist guanfacine, and the α1 -adrenoceptor agonist methoxamine, specifically stimulated GHRH secretion.
It is concluded that noradrenaline stimulates the release of GHRH at both α1 and α2 -adrenoceptors. 相似文献
Noradrenaline stimulated GHRH secretion in a dose-dependent manner in the concentration range 10
It is concluded that noradrenaline stimulates the release of GHRH at both α
3.
4.
5.
6.
Stroke prophylaxis in patients with moyamoya disease has not been described previously in Australia. Two cases are presented in which superficial temporal to middle cerebral arterial bypass has been successful in halting the progress of the disease. The presentation, investigation and management of this occlusive vasculopathy are discussed. 相似文献
7.
8.
9.
S. Tsagarakis A. Grossman P. N. Plowman A. E. Jones R. Touzel† L. H. Rees† J. A. H. Wass G. M. Besser 《Clinical endocrinology》1991,34(5):399-406
OBJECTIVE To determine the long-term effects of external beam megavoltage radiotherapy (RT: 4500 cGy via three portals at 180 cGy or less total daily dose) on endocrine function in prolactinomas. DESIGN Longitudinal study following radiotherapy with periodic re-assessment at regular intervals, at least 2 months off dopamine agonist therapy. PATIENTS Thirty-six female patients, age range 19-50 years, with either macroprolactinomas (12 patients) or microprolactinomas (24 patients), but without significant suprasellar extensions. MEASUREMENTS Clinical appraisal, and anterior and posterior pituitary assessment: basal levels at yearly intervals or less, with dynamic screening with TRH, LHRH and hypoglycaemic stimulation every 2-3 years. RESULTS Before RT, serum prolactin (PRL) levels ranged from 1150 to 34,000 mU/l; after RT (mean 8.5 years, range 3-14), serum PRL fell to normal (i.e. less than 360 mU/l) in 18 of the 36 patients (50%), and to just above the normal range (378-780 mU/l) in a further 10 (28%). Two patients had PRL levels at their last follow-up higher than those at presentation, with one patient showing evidence of tumour recurrence on CT scan. A total of eight of the 36 patients (23%) developed post-RT gonadal deficiency by the end of follow-up at 8 +/- 3.1 years (+/- SD, range 3-11), but six were aged over 40 years at that time. GH deficiency was frequent, occurring in 94% of patients, usually from 2 to 3 years post-RT, while TSH deficiency and reduced ACTH reserve was uncommon (each 14%), and occurred later. In the subgroup of 12 patients with macroprolactinomas, results were broadly comparable. CONCLUSIONS Megavoltage RT produces a progressive fall in serum prolactin in the great majority of patients with prolactinomas, with a relatively low incidence of TSH or ACTH deficiency. As it is now clear that dopamine agonist therapy alone provides sufficient management for microprolactinomas, RT may be used for the long-term control of macroprolactinomas, together with interim dopamine agonist therapy. It allows pregnancy to be safely undertaken but, in view of the delayed onset of gonadal deficiency, its administration should be timed with respect to the desired onset of conception in women. 相似文献
10.
Kinnison ML; Perler BA; Kaufman SL; Mitchell SE; Kadir S; Williams GM; White RI Jr 《Radiology》1986,160(3):727-730
In situ saphenous vein grafts are being used with increasing frequency for bypass procedures involving the femoral and popliteal arteries. Complications of these procedures include anastomotic stenoses and persistent arteriovenous fistulae that may result in failure of the graft. Balloon angioplasty and embolotherapy with detachable balloons were employed successfully in three or four recent cases of patients with complications from in situ grafts. Tailored angiography is essential for evaluating in situ grafts, and interventional techniques are extremely useful for managing complications. 相似文献